Printer Friendly

CELL THERAPEUTICS, INC. TO BEGIN PHASE I TRIALS IN CANADA

 SEATTLE, July 21 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) today said it will commence Phase I clinical trials with its novel therapeutic, CT-1501R, to protect against the toxic side effects of cancer chemotherapy at several leading centers in Canada.
 CT-1501R is a unique metabolite of pentoxifylline that is formed in the presence of quinolone antibiotics. It is thought to interfere with a unique intracellular signal transduction pathway -- called the Bursten Pathway after one of CTI's founders -- which contributes to abnormal cell conditions, including tumor growth, acute inflammation, and immune dysfunction.
 CTI believes that certain chemotherapeutic agents may exert non- specific toxic effects through the Bursten Pathway and that CT-1501R, by blocking key enzymes in the Pathway, may alleviate these effects.
 In June of this year CTI initiated four (4) Phase I clinical trials at ten (10) U.S. centers to assess CT-1501R in patients receiving bone marrow transplants (BMT's), high dose chemotherapy for solid tumors (e.g. lung cancer), and interleukin-2 for renal cell carcinoma or melanoma.
 CTI has already completed a Phase II trial in 75 BMT patients with the parent compound of CT-1501R, CT-1500, which is a proprietary combination of pentoxifylline and ciprofloxacin. These studies showed that CT-1500 was equivalent to G-CSF and GM-CSF in promoting neutrophil recovery, but superior in promoting recovery of platelets and erythrocytes. Extended Phase II trials of CT-1500 reported in March 1993 at ASCO demonstrated that, when administered with IL-2, CT-1500 significantly reduced IL-2's toxic side effects without diminishing its anti-tumor effectiveness. Because it is at least 100 times more potent than CT-1500, CT-1501R has been selected for further development.
 Preclinical animal studies support the effectiveness of CT-1501R as a multi-lineage hematopoietic stimulant. In those studies, the administration of CT-1501R with high-dose chemotherapy significantly accelerated neutrophil, platelet, and multi-lineage progenitor cells when compared with placebo. The drug also protected the animals from non-hematopoietic toxicity.
 The current IND will extend the company's clinical trial experience with CT-1501R in Canada.
 The company anticipates study completion by early fourth quarter of 1993, with initiation of randomized Phase II studies by early 1994.
 -0- 7/21/93
 /CONTACT: James A. Bianco, MD, of Cell Therapeutics, Inc, 206-284-5774, or Fred Spar of Kekst & Co., 212-593-2655, for Cell Therapeutics/


CO: Cell Therapeutics, Inc. ST: Washington IN: MTC SU:

TM-MG -- NY106 -- 4199 07/21/93 18:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 21, 1993
Words:387
Previous Article:ZEBRA SALES INCREASE 45 PERCENT, PROFITS UP 37 PERCENT
Next Article:UNITED AIRLINES UNION COALITION ISSUES STATEMENT ON UAL DISCUSSIONS
Topics:


Related Articles
CTI COMMENCES FOUR SIMULTANEOUS CLINICAL TRIALS
TRANSCEND THERAPEUTICS BEGINS PHASE II TRIAL OF PROCYSTEINE(R) FOR THE TREATMENT OF MULTIPLE ORGAN DYSFUNCTION (MOD)
RPR Gencell and Introgen Begin First p53 Phase II Trial in Gene Therapy; Plans Proceed to Conduct Phase II Trials in Head & Neck Cancer in U.S.,...
Cell Therapeutics to make milestone payment.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters